• Valion Bio raised $700,000 in a private placement with 3i on November 6, 2026.
• The sale included 700 shares of Series B Non-Voting Convertible Preferred Stock.
• 3i also received Series B Warrants to purchase 21,539 common shares at an initial exercise price of $0.5182 per share.
• The company will seek to register the underlying common shares within 30 days of closing, targeting effectiveness within 60 days.
• The deadline for additional closings under the Series B Preferred Purchase Agreement was extended to December 9, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008390), on November 09, 2026, and is solely responsible for the information contained therein.